The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation

Researchers performed a retrospective observational analysis of 2626 patients who underwent ASCT between 2017 and 2020 to clarify the prognostic impact of daratumumab before ASCT. The progression-free survival (PFS) rates and overall survival (OS) rates of the patients who could only achieve partial response or stable disease to progressive disease before ASCT in the patients who received daratumumab were significantly inferior to those of the patients in the group who didn’t receive it. However, in the patients who could obtain complete response or very good partial response with daratumumab treatment before ASCT, both the PFS and OS were significantly improved.